Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
10.3904/kjim.2015.30.2.170
- Author:
Yu Jung JO
1
;
Kyung Ah KIM
;
June Sung LEE
;
Nam Hoon KIM
;
Won Ki BAE
;
Tae June SONG
;
Jeong Wook KIM
Author Information
1. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. kakim@paik.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatitis B, chronic;
Entecavir;
Partial virological response;
Nucleos(t)ide analogue-experienced
- MeSH:
Adult;
Antiviral Agents/adverse effects/*therapeutic use;
Biomarkers/blood;
DNA, Viral/blood;
Drug Resistance, Viral;
Female;
Guanine/adverse effects/*analogs & derivatives/therapeutic use;
Hepatitis B virus/*drug effects/genetics/growth & development;
Hepatitis B, Chronic/diagnosis/*drug therapy;
Humans;
Male;
Middle Aged;
Retrospective Studies;
Time Factors;
Treatment Outcome;
Viral Load
- From:The Korean Journal of Internal Medicine
2015;30(2):170-176
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The clinical outcome of patients with a partial virological response (PVR) to entecavir (ETV), in particular nucloes(t)ide analogue (NA)-experienced patients, has not been thoroughly investigated. The aim of the present study was to assess long-term outcomes in NA-naive and NA-experienced chronic hepatitis B patients with a PVR to ETV. METHODS: Chronic hepatitis B patients treated with ETV (0.5 mg/day) for at least 1 year were enrolled retrospectively. PVR was defined as a decrease in hepatitis B virus (HBV) DNA titer of more than 2 log10 IU/mL, yet with residual serum HBV DNA, as determined by real time-polymerase chain reaction, at week 48 of ETV therapy. RESULTS: A total of 202 patients (127 NA-naive and 75 NA-experienced, male 70.8%, antigen positive 53.2%, baseline serum HBV DNA 6.2 +/- 1.5 log10 IU/mL) were analyzed. Twenty-eight patients demonstrated a PVR. The PVR was associated with a high serum HBV DNA titer at baseline and at week 24. Virological response (< 60 IU/mL) was achieved in 46.2%, 61.5%, 77.6%, and 85% of patients with PVR at week 72, 96, 144, and 192, respectively. Resistance to antivirals developed in two NA-experienced patients. Failure of virological response (VR) in patients with PVR was associated with high levels of serum HBV DNA at week 48. CONCLUSIONS: Patients with PVR to ETV had favorable long-term virological outcomes. The low serum level of HBV DNA (< 200 IU/mL) at week 48 was associated with subsequent development of a VR in patients with PVR to ETV.
